Early, Precise and Non-Invasive Prostate Cancer Detection

Pre-FDA approved, Prostac™ is a patented, straightforward and non-invasive molecular-based blood test for the early, precise detection** of prostate cancer.  From blood drawn at the Doctor's office, Prostac™: ​

​

• Detects if a man has prostate cancer and the aggressiveness of the cancer if detected.​

​​​

• Identifies a man's predisposition to developing prostate cancer.

​

• ​Categorizes the diagnosed prostate cancer into distinct risk groups ranging from indolent to aggressive castration-resistant.

​​

• Aids physicians in making better treatment decisions.

 
 
 
 
 
Prostac™ can replace the Prostate-Specific Antigen (PSA) test for men who want a to know with confidence whether they have prostate cancer.  This can include men who are 'at risk' for prostate cancer based on their family history, have an African ancestry, or who work in jobs which have shown to have higher rates of prostate cancer.      
​
Men with a higher PSA score or who have a previous prostate cancer diagnosis can also use Prostac™ to verify a prostate cancer diagnosis. Men testing negative with Prostac™ would then avoid the expensive, intrusive and often harmful screening tests, and even more expensive and potentially life-damaging overtreatments. 

Prostac™ takes away the worry and stress of an uncertain prostate cancer diagnosis and gives men the peace of mind and the confidence to take control of their personal health and well-being.   

** Note: In preliminary data analysis, Prostac™ is a better predictor of prostate cancer than PSA with better specificity, sensitivity and accuracy.